RU2019139387A - Способы селективного лечения астмы с использованием антагонистов il-17 - Google Patents
Способы селективного лечения астмы с использованием антагонистов il-17 Download PDFInfo
- Publication number
- RU2019139387A RU2019139387A RU2019139387A RU2019139387A RU2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- patient
- antagonist
- treatment
- less
- Prior art date
Links
- 108050003558 Interleukin-17 Proteins 0.000 title claims 44
- 102000013691 Interleukin-17 Human genes 0.000 title claims 44
- 239000005557 antagonist Substances 0.000 title claims 38
- 238000000034 method Methods 0.000 title claims 28
- 208000006673 asthma Diseases 0.000 title claims 16
- 210000002966 serum Anatomy 0.000 claims 30
- 108060003951 Immunoglobulin Proteins 0.000 claims 24
- 102000018358 immunoglobulin Human genes 0.000 claims 24
- 239000012472 biological sample Substances 0.000 claims 18
- 210000003979 eosinophil Anatomy 0.000 claims 12
- 210000005259 peripheral blood Anatomy 0.000 claims 11
- 239000011886 peripheral blood Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000004458 analytical method Methods 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 102000004554 Interleukin-17 Receptors Human genes 0.000 claims 2
- 108010017525 Interleukin-17 Receptors Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000006249 magnetic particle Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501806P | 2017-05-05 | 2017-05-05 | |
| US62/501,806 | 2017-05-05 | ||
| PCT/IB2018/053106 WO2018203289A1 (en) | 2017-05-05 | 2018-05-04 | Methods of selectively treating asthma using il-17 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019139387A true RU2019139387A (ru) | 2021-06-07 |
Family
ID=62245372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019139387A RU2019139387A (ru) | 2017-05-05 | 2018-05-04 | Способы селективного лечения астмы с использованием антагонистов il-17 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10676522B2 (enExample) |
| EP (1) | EP3619536A1 (enExample) |
| JP (1) | JP2020518604A (enExample) |
| KR (1) | KR20190142398A (enExample) |
| CN (1) | CN110582702A (enExample) |
| AU (1) | AU2018263159A1 (enExample) |
| BR (1) | BR112019023141A2 (enExample) |
| CA (1) | CA3062179A1 (enExample) |
| CL (1) | CL2019003161A1 (enExample) |
| MX (1) | MX2019013160A (enExample) |
| RU (1) | RU2019139387A (enExample) |
| TW (1) | TW201842933A (enExample) |
| WO (1) | WO2018203289A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689907A1 (en) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| JP2023521909A (ja) * | 2020-04-17 | 2023-05-25 | イーライ リリー アンド カンパニー | 呼吸器疾患の治療 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308324D0 (en) | 2003-04-10 | 2003-05-14 | Piezoptic Ltd | A chemical sensing device |
| CN1898564A (zh) * | 2003-12-24 | 2007-01-17 | 惠氏公司 | 治疗哮喘的方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| HUE039353T2 (hu) | 2005-12-13 | 2018-12-28 | Lilly Co Eli | Anti-IL-17 ellenanyagok |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| US20110123530A1 (en) * | 2008-03-31 | 2011-05-26 | Arron Joseph R | Compositions and methods for treating and diagnosing asthma |
| RU2539029C2 (ru) | 2008-09-29 | 2015-01-10 | Роше Гликарт Аг | Антитела против интерлейкина 17 (ил-17) человека и их применение |
| CA2897682C (en) | 2013-02-08 | 2023-03-14 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| AU2014340129A1 (en) * | 2013-10-23 | 2016-05-26 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
| US20160000936A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| FI3191120T3 (fi) * | 2014-09-10 | 2024-07-10 | Novartis Ag | Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla |
| GB201508832D0 (en) | 2015-05-22 | 2015-07-01 | Novartis Ag | A method for detecting an analyte |
-
2018
- 2018-05-03 TW TW107114983A patent/TW201842933A/zh unknown
- 2018-05-03 US US15/969,952 patent/US10676522B2/en active Active
- 2018-05-04 JP JP2019560115A patent/JP2020518604A/ja active Pending
- 2018-05-04 BR BR112019023141-2A patent/BR112019023141A2/pt not_active Application Discontinuation
- 2018-05-04 MX MX2019013160A patent/MX2019013160A/es unknown
- 2018-05-04 AU AU2018263159A patent/AU2018263159A1/en not_active Abandoned
- 2018-05-04 KR KR1020197035578A patent/KR20190142398A/ko not_active Abandoned
- 2018-05-04 RU RU2019139387A patent/RU2019139387A/ru not_active Application Discontinuation
- 2018-05-04 EP EP18727435.2A patent/EP3619536A1/en not_active Withdrawn
- 2018-05-04 CA CA3062179A patent/CA3062179A1/en not_active Abandoned
- 2018-05-04 CN CN201880029544.7A patent/CN110582702A/zh active Pending
- 2018-05-04 WO PCT/IB2018/053106 patent/WO2018203289A1/en not_active Ceased
-
2019
- 2019-11-04 CL CL2019003161A patent/CL2019003161A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110582702A (zh) | 2019-12-17 |
| US20180319881A1 (en) | 2018-11-08 |
| US10676522B2 (en) | 2020-06-09 |
| TW201842933A (zh) | 2018-12-16 |
| MX2019013160A (es) | 2020-02-05 |
| EP3619536A1 (en) | 2020-03-11 |
| BR112019023141A2 (pt) | 2020-07-28 |
| CA3062179A1 (en) | 2018-11-08 |
| CL2019003161A1 (es) | 2020-02-07 |
| JP2020518604A (ja) | 2020-06-25 |
| AU2018263159A1 (en) | 2019-11-07 |
| KR20190142398A (ko) | 2019-12-26 |
| WO2018203289A1 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eghbali-Fatourechi et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | |
| CN102576015B (zh) | 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物 | |
| Thoren | Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease | |
| RU95108591A (ru) | Способ определения состояния сепсисного заболевания | |
| AR063125A1 (es) | Ensayo elisa para la deteccion de vegf | |
| WO2011135024A1 (en) | Methods for detecting antibodies | |
| JP6812521B2 (ja) | クロモグラニンａを検出するための免疫アッセイ法および抗体 | |
| Chan et al. | Rapid analysis of fatty acid-binding proteins with immunosensors and immunotests for early monitoring of tissue injury | |
| CN118063608A (zh) | 针对三碘甲状腺原氨酸的单克隆抗体、基于其的检测试剂及其应用 | |
| CN109804081A (zh) | 一种复合靶标-肿瘤血清核酸配基检测方法及试剂盒 | |
| RU2019139387A (ru) | Способы селективного лечения астмы с использованием антагонистов il-17 | |
| US20150132744A1 (en) | Methods of detecting cells latently infected with hiv | |
| JP2020518604A5 (enExample) | ||
| CN116482345B (zh) | 用于检测双靶点药物受体占有率的方法 | |
| CN118994407A (zh) | 抗噻奈普汀的抗体或其抗原结合片段及其应用 | |
| WO2024226899A1 (en) | Diagnosis of late-stage hepatocellular carcinoma | |
| Krischer et al. | A Comparative Analysis of the Sensitivity, Specificity, Concordance, and the 5-year Predictive Power of Diabetes-related Autoantibody Assays | |
| US20190064177A1 (en) | Incorporating competitive binding information into molecular array analysis to generate function networks of interactions | |
| EP4286850A1 (en) | Immunological assay method | |
| AU2017334408B2 (en) | Point of care assays | |
| RU2803276C1 (ru) | Способ прогнозирования когнитивных нарушений у пациентов с сотрясением головного мозга и ушибом головного мозга лёгкой степени тяжести | |
| CA2870320C (en) | Rapid test for cellular fibronectin | |
| WO2001086292A2 (en) | Ipg assay | |
| KR20250015147A (ko) | 자폐증 장애 진단용 조성물 및 키트 | |
| TWI741914B (zh) | 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210505 |